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Most drug research in AD has been directed at providing
symptomatic cognitive enhancement through a variety of
neurotransmitter manipulations. Cholinergic neurotrans-
mission has been most frequently targeted in drug devel-
opment for a variety of reasons. There is a well
characterized degeneration of the acetylcholine (Ach) syn-
thesizing neurons in the basal forebrain region and their
cortical synaptic connections in AD. The severity of AD
has been correlated to the degree of decline of choline
acetyltransferase (CAT) the key synthetic enzyme of Ach.
Impairment of number and function of muscarinic and
nicotinic receptors have been implicated in the cognitive
impairment of AD. It has been the interventions directed
at the inhibition of cholinesterases (ChE) that have been
the most successful to date at producing symptomatic
benefit, measurably enhancing cognitive function. During
recent years, treatment of cognitive impairment in AD
patients has been made possible by the introduction of
ChE inhibitors, such as rivastigmine, donepezil and
galanthamine. The drugs improve memory, cognitive and
global function in AD, probably augmenting cholinergic
function. ChE inhibitors differ substantially in their phar-
macological properties which may translate into differ-
ences in clinical efficacy, safety and tolerability.
Galanthamine show a dual mode of action by the allos-
teric modulation, with clinically meaningful improve-
ment on cognition in AD, Lewy body dementia,
Parkinson's disease dementia and vascular dementia.
Rivastigmine has demonstrated a strong action as a dual
AChE and BuChE inhibitor. Recent reports focus on the
role of Butirylcholinesterase (BuChE) in AD. The activity
of this enzyme increases during the progression of the dis-
ease while AChE decreases. Inhibition of both enzymes
may have more prolonged clinical results. Recent findings
indicate that both AChE and BuChE in addition to their
role in neurotransmission may play a role in the forma-
tion of amyloid plaques. It is found that the activity of
BuChE substantially increases in the affected areas of the
brain. The reason for this increase is under research. It is
believed that inhibition of AChE and BuChE can delay
deterioration in AD patients. In addition to the cognitive
and functional symptoms treatment with ChE inhibition
may also improve the behavioural and psychiatric symp-
toms of AD and other dementias. Agitation, irritability,
anxiety and depression may improve. Dual ChE inhibitors
of AchE and BuChE can also improve delusions and hal-
lucinations. This is very important especially in Levy body
where antipsychotics can cause serious adverse events.
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